RecruitingNot Applicable

CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases

Canada60 participantsStarted 2025-12-12

Plain-language summary

This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease involvement, including leptomeningeal disease (Cohort A), parenchymal brain metastases (Cohort B), and no evidence of CNS metastases (Cohort C).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients in Cohort A will have leptomeningeal metastatic disease (LMD) with or without parenchymal brain metastases.
✓. Patients in Cohort B will have parenchymal brain metastases but no evidence of LMD.
✓. Patients in Cohort C will have metastatic solid tumours no CNS metastases (i.e. no LMD nor brain metastases).

What they're measuring

To estimate the proportion of patients with solid tumours and CNS metastases (either meeting criteria for Cohort A or B), or no CNS metastases (Cohort C) who have positive CSF cytology, positive ctDNA, and/or positive CTCs

Timeframe: From enrollment to the CSF and plasma collection, within 2-4 weeks

Trial details

NCT IDNCT07476781

SponsorSunnybrook Health Sciences Centre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Katarzyna Jerzak, Dr

416-480-5000 katarzyna.jerzak@sunnybrook.ca

View on ClinicalTrials.gov More Solid Tumor Malignancies trials